Efficacy and safety of new oral anticoagulants: Position of gastroenterologist

Cover Page

Cite item

Full Text

Abstract

The prevention of thromboembolism is the leading goal in the management of atrial fibrillation (AF) patients. Oral anticoagulants (OAC) has been using in the treatment of AF patients for a long time according the modern clinical recommendations. Recently, new direct oral anticoagulants (NOAC) have been increasingly used in the treatment and prevention of thrombo-embolism in AF patients. However, the problem of bleeding prevention in anticoagulated patients (primarily for gastrointestinal tract) is still unresolved. The authors analyzed the results of evidence-based medicine for assessing the risk of gastrointestinal bleeding in anticoagulated patients with NOACs.

About the authors

I. G. Bakulin

North-Western State Medical University named I.I. Mechnikov

Author for correspondence.
Email: ochizhova@gmail.com
Russian Federation, Saint Petersburg

L. N. Belousova

North-Western State Medical University named I.I. Mechnikov

Email: ochizhova@gmail.com
Russian Federation, Saint Petersburg

I. G. Pakhomova

North-Western State Medical University named I.I. Mechnikov

Email: ochizhova@gmail.com
Russian Federation, Saint Petersburg

O. Yu. Chizhova

North-Western State Medical University named I.I. Mechnikov

Email: ochizhova@gmail.com
Russian Federation, Saint Petersburg

References

  1. WHO Global InfoBase. URL: http:www.infobase.who.int.
  2. Стратегия профилактики и контроля неинфекционных заболеваний и травматизма в Российской Федерации. - М., 2008. - 24 с. [Strategiya profilaktiki i kontrolya neinfekcionnyh zabolevanij i travmatizma v Rossijskoj Federacii. Moscow; 2008. 24 p. (In Russ.)]
  3. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837-847. doi: 10.1161/CIRCULATIONAHA.113.005119.
  4. Colilla S, Crow A, Petkun W, et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013;112(8):1142-1147. doi: 10.1016/j.amjcard.2013.05.063.
  5. Andersson T, Magnuson A, Bryngelsson IL, et al. All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995-2008: a Swedish nationwide long-term casecontrol study. Eur Heart J. 2013;34(14):1061-1067. doi: 10.1093/eurheartj/ehs469.
  6. Benjamin EJ, Wolf PA, D’Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98(10):946-952.
  7. CardioPulse Articles. Anticoagulants reduce risk of death in atrial fibrillation patients by 38%. Eur Heart J. 2016;37:860-867.
  8. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest. 2010;137(2):263-272. doi: 10.1378/chest.09-1584.
  9. Hughes M, Lip GY. Hughes M. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost. 2008;99(2):295-304. doi: 10.1160/TH07-08-0508.
  10. ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESCEndorsed by the European Stroke Organisation (ESO). Eur Heart J. 2016;(38):2893-2962.
  11. Шубик Ю.В. Особенности профилактики тромбоэмболических осложнений у больных с фибрилляцией предсердий в России // Вестник аритмологии. - 2017. - Т. 87. - С. 5-6. [Shubik YuV. Peculiar features of prevention of thromboembolic events in atrial fibrillation in russia. Journal of arrhythmology. 2017;87:5-6. (In Russ.)]
  12. Сулимов В.А., Голицын С.П., Панченко Е.А., и др. Диагностика и лечение фибрилляции предсердий, рекомендации РКО, ВНОА и АССХ // Рос. кардиол. журн. - 2013. - Т. 18. - № 4 53(102). - 100 с. [Sulimov VA, Golicyn SP, Panchenko EA, et al. Diagnostika i lechenie fibrillyacii predserdij, rekomendacii RKO, VNOA i ASSKH. Russian Journal of Cardiology. 2013;18(4 53(102)):100. (In Russ.)]
  13. Granger CB, Alexander JH, McMurray JJ, et al. For the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992. doi: 10.1056/NEJMoa1107039.
  14. Connolly SJ, Eikelboom J, Joyner C, et al. AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806-817. doi: 10.1056/NEJMoa1007432.
  15. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151. doi: 10.1056/NEJMoa0905561.
  16. Patel MR, Mahaffey KW, Garg J, et al. For the ROCKET-AF Investigators. Rivaroxaban versus warfarin in nonvalvularatrial fibrillation. N Engl J Med. 2011;365(10):883-891. doi: 10.1056/NEJMoa1009638.
  17. Edupuganti S, Xie C, Wyrzykowski M, et al. Bleeding Complications in Patients Receiving Direct Oral Anticoagulant Therapy in the Post Clinical Trial General Practice. American Journal of Clinical and Experimental Medicine. 2017;5(3):64-68. doi: 10.11648/j.ajcem.20170503.12.
  18. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151(3):713-719. doi: 10.1016/j.ahj.2005.04.017.
  19. Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Antic-oagulation and risk factors in atrial fibrillation) Study. J Am Coll Cardiol. 2011;58:395-401. doi: 10.1016/j.jacc.2011.03.031.
  20. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093-100. doi: 10.1378/chest.10-0134.
  21. Omran H, Bauersachs R, Rubenacker S, et al. The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation. Results from the national multicentre BNK Online bRiDging REgistRy (BORDER). Thromb Haemost. 2012;108:65-73.
  22. Miller CS, Grandi SM, Shimony A, et al. Meta-analysis of Efficacy and Safety of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) Versus Warfarin in Patients With Atrial Fibrillation. Am J Cardiol. 2012;110(3):453-460. doi: 10.1016/j.amjcard.2012.03.049.
  23. Holster IL, Valkhoff VE, Kuipers EJ, et al. New oral anticoagulants increase risk for gastrointestinal bleeding: A systematic review and metaanalysis. Gastroenterology. 2013;145(1):105-112. doi: 10.1053/j.gastro.2013.02.041.
  24. Miller CS, Dorreen A, Martel M, et al. Risk of gastrointestinal bleeding in patients taking non-vitamin K antagonist oral anticoagulants: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2017;15:1674-1683. doi: 10.1016/j.cgh.2017.04.031.
  25. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093-2104. doi: 10.1056/NEJMoa1310907.
  26. Laine L. Bleeding with direct oral anticoagulants: The gastrointestinal tract and beyond. Clinical Gastroenterology and Hepatology. 2017;15(11):1665-1667. doi: 10.1016/j.cgh.2017.06.041.
  27. Vaduganathan M, Bhatt DL. Gastrointestinal bleeding with oral anticoagulation: understanding the scope of the problem. Clin Gastroenterol Hepatol. 2017;15:691-693. doi: 10.1016/j.cgh.2016.12.033.
  28. Xu W, Hu S, Wu T. Risk analysis of new oral anticoagulants for gastrointestinal bleeding and intracranial hemorrhage in atrial fibrillation patients: a systematic review and network meta-analysis. J Zhejiang Univ Sci B. 2017;18(7):567-576. doi: 10.1631/jzus.B1600143.
  29. Каратеев А.Е., Насонов Е.Л., Яхно Н.Н., и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике» // Современная ревматология. - 2015. - № 9(1). - С. 4-23. [Karateev AE, Nasonov EL, Yakhno NN. Clinical guidelines “Rational use of nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice”. Modern Rheumatology. 2009;(9(1)):507. (In Russ.)]
  30. Crofford LJ. Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther. 2013;15(Suppl. 3):S2. doi: 10.1186/ar4174.
  31. Кропачева Е.С, Панченко Е.П. Основы терапии антагонистами витамина К для практикующих врачей // РМЖ. - 2009. - № 8. - С. 507. [Kropacheva ES, Panchenko EP. Osnovy terapii antagonistami vitamina K dlya praktikuyushchih vrachej. RMZH. 2009;(8):507. (In Russ.)]

Copyright (c) 2018 Bakulin I.G., Belousova L.N., Pakhomova I.G., Chizhova O.Y.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies